Subtype
Malignant Ovarian Epithelial Tumor
CI-CAN-00001157Explore in graph →
270 active trials2 approved drugs26 evidence items
- NCIt
- C40026
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001157Explore in graph →
Clinical trials
897 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04787289 | A Comparison of 2 Standard Doses of Bevacizumab in Combination With Chemotherapy in Epithelial Ovarian Cancer | unknown | Phase 2 | 244 | British Columbia Cancer AgencyOTHER | 1 | Aug 7, 2024 | clinicaltrials |
| NCT05610501 | Ultrasound-guided Tru-Cut Biopsy in Pelvic Masses. | unknown | — | 200 | Universitaire Ziekenhuizen KU LeuvenOTHER | 4 | Jul 3, 2024 | clinicaltrials |
| NCT05472857 | Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression | unknown | Phase 1 | 30 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT06277947 | Administration of Hyperthermic Intraperitoneal Chemotherapy in the General Ward(GARD-HIPEC) | unknown | N/A | 92 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 26, 2024 | clinicaltrials |
| NCT06243185 | Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors | unknown | Phase 2 | 30 | Fengzhi FengOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06241105 | Lenvatinib Plus Toripalimab for Platinum-Resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 69 | Peking Union Medical College HospitalOTHER | 1 | Feb 5, 2024 | clinicaltrials |
| NCT05212779 | Predicting the Risk of Ovarian Cancer Recurrence Using Circulating Tumor DNA to Assess Residual Disease | unknown | — | 45 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT06236958 | Effect of Early Enteral Nutrition on Postoperative Recovery of Ovarian Cancer Patients | unknown | — | 200 | Luo ChengyanOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05489926 | A Study to Explore Pamiparib Treatment in Epithelial Ovarian Cancer After Prior PARP Inhibitor Exposure | unknown | Phase 2 | 15 | Zhejiang Cancer HospitalOTHER | 1 | Jan 26, 2024 | clinicaltrials |
| NCT06223763 | SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery(SUROVA) | unknown | — | 5,000 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT05949424 | OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults(OPTI-DOSE) | unknown | Phase 4 | 30 | University Medical Center GroningenOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT02584478 | Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)(AL3818) | unknown | Phase 3 | 294 | Advenchen Laboratories, LLCINDUSTRY | 6 | Nov 8, 2023 | clinicaltrials |
| NCT05498597 | AMT-151 in Patients With Selected Advanced Solid Tumours | unknown | Phase 1 | 30 | Multitude Therapeutics Inc.INDUSTRY | 2 | Oct 19, 2023 | clinicaltrials |
| NCT06085456 | Individualized Health Management of Epithelial Ovarian Cancer: A Retrospective Study | unknown | — | 1,000 | RenJi HospitalOTHER | 1 | Oct 17, 2023 | clinicaltrials |
| NCT06055348 | SC0191 Plus Chemotherapy in Advanced Ovarian Canceradvanced Ovarian Cancer | unknown | Phase 1 / Phase 2 | 112 | Biocity Biopharmaceutics Co., Ltd.INDUSTRY | 0 | Sep 26, 2023 | clinicaltrials |
| NCT06010667 | A Prospective, Randomized Controlled Study of Cyclophosphamide, Bevacizumab With or Without Envafolimab in Recurrent Epithelial Ovarian Cancer (EOC), Fallopian Tube Cancer, and Primary Peritoneal Cancer | unknown | — | 60 | Hebei Medical University Fourth HospitalOTHER | 1 | Aug 24, 2023 | clinicaltrials |
| NCT05856409 | Clinical Application of 68Ga-FAPI PET Imaging in Detection of Ovarian Cancer Recurrence | unknown | — | 20 | RenJi HospitalOTHER | 1 | Aug 16, 2023 | clinicaltrials |
| NCT05874115 | Development of a Biomarker to Predict the Efficacy of Anti-angiogenic Therapy in Ovarian Cancer(OutCoME) | unknown | — | 75 | Centro di Riferimento Oncologico - AvianoOTHER | 1 | Aug 3, 2023 | clinicaltrials |
| NCT04201561 | High Dose Inorganic Selenium for Preventing Chemotherapy Induced Peripheral Neuropathy(SELENIUM) | unknown | Phase 3 | 68 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04678102 | Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)(CREATIVE) | unknown | Phase 1 | 36 | Seoul National University HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT05877911 | Effect of Sodium Thiosulfate on Nephrotoxicity of Cisplatin Intraperitoneal Heat-perfusion Chemotherapy | unknown | Phase 2 | 110 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | May 26, 2023 | clinicaltrials |
| NCT05801263 | ctDNA Methylation for Epithelial Ovarian Cancer | unknown | — | 5,000 | Lei LiOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT05801276 | ctDNA Methylation for Detecting Ovarian Cancer | unknown | — | 1,400 | Lei LiOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT04369352 | Register to Describe the Treatment Pattern of Platinum-sensitive Relapsed Epithelial Ovarian Cancer Patients in Austria | unknown | — | 150 | Medical University InnsbruckOTHER | 1 | Mar 28, 2023 | clinicaltrials |
| NCT03321188 | Heated Intraperitoneal Chemotherapy in Primary Ovarian Cancer Patients | unknown | Phase 2 | 20 | Andrea JewellOTHER | 1 | Feb 6, 2023 | clinicaltrials |
| NCT05622890 | A Single-arm Clinical Trial of IMGN853 in Chinese Adult Patients With Platinum-resistant, Epithelial Ovarian Cancer | unknown | Phase 3 | 35 | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 21, 2022 | clinicaltrials |
| NCT05591560 | Itraconazole in Advanced Ovarian Cancer | unknown | N/A | 66 | Tanta UniversityOTHER | 1 | Oct 24, 2022 | clinicaltrials |
| NCT05576519 | Immunohistochemical Expression of Epithelial Cell Adhesion Molecule (EpCAM) in Epithelial Ovarian Carcinoma | unknown | — | 50 | Sohag UniversityOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT04015739 | Tri Association in Patient With Advanced Epithelial Ovarian Cancer in Relapse(BOLD) | unknown | Phase 2 | 74 | ARCAGY/ GINECO GROUPOTHER | 1 | Aug 17, 2022 | clinicaltrials |
| NCT04864431 | Vitamin D and Pre Cachexia and Cancer Cachexia in Epithelial Ovarian Cancer(VitD) | unknown | N/A | 54 | Indonesia UniversityOTHER | 1 | Jun 22, 2022 | clinicaltrials |
| NCT05422183 | Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer | unknown | Phase 2 | 20 | Zhongda HospitalOTHER | 1 | Jun 16, 2022 | clinicaltrials |
| NCT05385068 | A Phase II Trial to Explore Niraparib and Anlotinib Maintenance Retreatment in Platinum-Sensitive Recurrent Ovarian Cancer Patients Previously Treated With PARPi(t) | unknown | Phase 2 | 35 | Peking Union Medical College HospitalOTHER | 0 | May 23, 2022 | clinicaltrials |
| NCT02033616 | Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas | unknown | Phase 2 | 99 | Aivita Biomedical, Inc.INDUSTRY | 1 | Apr 25, 2022 | clinicaltrials |
| NCT05311579 | Niraparib Plus Anlotinib for Recurrent Ovarian Cancer | unknown | Phase 2 | 36 | Lei LiOTHER | 1 | Apr 13, 2022 | clinicaltrials |
| NCT05310344 | Albumin-bound Paclitaxel and Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer | unknown | Phase 2 | 50 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05310357 | Chromosomal Instability in Ovarian Cancer | unknown | — | 300 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT05310370 | HRD and Resistance to PAPPi in EOC Patients | unknown | — | 400 | Lei LiOTHER | 1 | Apr 4, 2022 | clinicaltrials |
| NCT03542669 | Study of 6b11-OCIK Injection Treatment in Patients With Recurrent Drug-resistant Ovarian Cancer | unknown | Phase 1 | 9 | Peking University People's HospitalOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT05180851 | Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study(YSCH-01) | unknown | Early Phase 1 | 28 | Shanghai Fengxian District Central HospitalOTHER | 1 | Feb 1, 2022 | clinicaltrials |
| NCT05187208 | PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer(POLO) | unknown | Phase 4 | 102 | Seoul National University HospitalOTHER | 0 | Jan 26, 2022 | clinicaltrials |
| NCT05145218 | A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian Cancer | unknown | Phase 3 | 405 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Dec 8, 2021 | clinicaltrials |
| NCT05146505 | miRNAs in High Grade Serous Ovarian Cancer(MIROC) | unknown | — | 150 | IRCCS Azienda Ospedaliero-Universitaria di BolognaOTHER | 1 | Dec 6, 2021 | clinicaltrials |
| NCT04620954 | Clinical Trial of Chemotherapy, Oregovomab and Nivolumab in Patients With Epithelial Cancer of Ovarian, Tubal or Peritoneal Origin(ORION-02) | unknown | Phase 1 / Phase 2 | 31 | National Cancer Centre, SingaporeOTHER | 1 | Dec 1, 2021 | clinicaltrials |
| NCT05069818 | Variance of HRD From Paired Ovarian Cancer(HOPEII) | unknown | — | 50 | Xiaoxiang ChenOTHER | 1 | Oct 6, 2021 | clinicaltrials |
| NCT00108745 | Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer | unknown | Phase 3 | 1,157 | GOG FoundationNETWORK | 1 | Sep 30, 2021 | clinicaltrials |
| NCT00954174 | Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer | unknown | Phase 3 | 637 | GOG FoundationNETWORK | 2 | Sep 30, 2021 | clinicaltrials |
| NCT05059782 | Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer | unknown | N/A | 150 | Xi'an Jiaotong UniversityOTHER | 1 | Sep 28, 2021 | clinicaltrials |
| NCT04986371 | Real-world Study of Niraparib Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer(RENI-1) | unknown | — | 300 | Ling-Ying WuUNKNOWN | 0 | Aug 2, 2021 | clinicaltrials |
| NCT04983550 | Efficacy and Safety of SG001 Combined With PLD in Patients With Platinum-resistant Relapsed EOC | unknown | Phase 2 | 126 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY | 0 | Jul 30, 2021 | clinicaltrials |
| NCT02785250 | Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer | unknown | Phase 1 / Phase 2 | 85 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Jun 18, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Aug 7, 2024source: clinicaltrials